SCHEMBL21166946

SCHEMBL21166946

CC(C)N[C@@H](CCN)C(=O)C(C)C

nearest known ligand 0.40

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GABRR1 P24046 2/20 0.40
GABBR2 O75899 2/20 0.34
GABBR1 Q9UBS5 2/20 0.34
DPP7 Q9UHL4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12762368 1.00 GABRR1 (0.40) GABRR1GABBR2GABBR1DPP7
SCHEMBL25462341 0.88 FOLH1 (0.34) GABRR1DPP7
SCHEMBL21166944 0.88 FOLH1 (0.34) GABRR1DPP7
SCHEMBL13254054 0.88 FOLH1 (0.34) GABRR1DPP7
SCHEMBL27250343 0.86 FOLH1 (0.40)
SCHEMBL13573523 0.86 FOLH1 (0.40)
SCHEMBL7604714 0.86 FOLH1 (0.40)
SCHEMBL26731701 0.85 GABRR1 (0.41) GABRR1GABBR2GABBR1DPP7
SCHEMBL757850 0.85 GABRR1 (0.41) GABRR1GABBR2GABBR1DPP7
SCHEMBL19361692 0.83 TDP1 (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10793601-B2 Therapeutic spalt-like transcription factor 4 (SALL4) peptide NATIONAL UNIVERSITY OF SINGAPORE (SG) 2020-10-06 US disclosed
US-20190218253-A1 Therapeutic SALL4 Peptide AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218253-A1 Therapeutic SALL4 Peptide RBBP4, RBBP5, RB1 GABRR1 1991/4885GABBR2 3261/4885GABBR1 3762/4885
US-10793601-B2 Therapeutic spalt-like transcription factor 4 (SALL4) peptide RBBP4, SALL4, RBBP5 GABRR1 1629/4885GABBR2 1388/4885GABBR1 1804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.